Blog

Intelligent Bio Solutions Strengthens UK Market Position with Addition of Key Manufacturing Accounts

Jul 9, 2024 | blog

NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical know-how firm delivering clever, speedy, non-invasive testing options, in the present day introduced the  addition of a number of key accounts within the UK manufacturing sector. This announcement follows current successes within the warehouse and logistics, transport and infrastructure, and retail sectors because the Company’s progress momentum continues.

Recent additions to INBS’ buyer account portfolio embrace three main producers, every with distinctive wants and challenges in sustaining office security. A number one automotive elements producer with 5 websites and 1,200 staff has transitioned from third-party urine testing to the Intelligent Fingerprinting Drug Screening System. The earlier methodology concerned lengthy wait occasions for testing call-outs, which delayed crucial security checks. The firm has improved testing and operational effectivity by adopting INBS’ immediate, on-site fingerprint drug testing. Other account  additions embrace a significant packaging producer working 4 websites with roughly 900 staff and a widely known beverage producer with two websites and 350 staff. Neither firm had beforehand carried out drug testing protocols. Both firms required a fast, non-invasive methodology to check workers, and fingerprint drug testing offered the perfect answer, permitting for speedy and dependable testing.

Doug Heath, Vice President of Global Sales at INBS, commented, “Our Intelligent Fingerprinting Drug Screening System provides businesses within the manufacturing sector with an efficient and non-invasive method to enhance workplace safety, ensuring that safety-critical staff are fit for duty at all times. We are proud to support these companies in their commitment to maintaining a safe and productive work environment by providing an effective and easy-to-implement solution.”

Drug and alcoholassociated  impairment within the  office  has been  linked  to an elevated danger of harm for employees. The Health and Safety Executive (HSE) reported that the UK manufacturing sector had a statistically important price of non-fatal office accidents, with 1,740 accidents per 100,000 employees in 2022/23. These figures spotlight the necessity for efficient drug screening strategies to make sure employee security.

INBS’ modern answer addresses office security issues by offering correct, on-the-spot testing. The Intelligent Fingerprinting Drug Screening System screens for widespread medication of abuse, together with hashish, opiates, cocaine, and methamphetamine, utilizing sweat from the fingertips. This methodology provides a non-invasive, speedy different to conventional testing strategies, making certain staff are match for obligation.

About Intelligent Bio Solutions Inc.  

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical know-how firm delivering modern, speedy, non-invasive testing options. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize transportable testing by fingerprint sweat evaluation, which has the potential for broader functions in further fields. Designed as a hygienic and cost-effective system, the check screens for current use of medicine generally discovered within the office, together with opiates, cocaine, methamphetamine, and hashish. With pattern assortment in seconds and ends in below ten minutes, this know-how can be a priceless device for employers in safety-critical industries. Additionally, the Company’s biosensor platform has the potential to check for numerous indications, starting from immunological circumstances to communicable ailments. The Company’s present buyer segments embrace building, manufacturing and engineering, transport and logistics companies, drug remedy organizations, and coroners.  

For extra info, go to:¯http://www.ibs.inc/  

Forward-Looking Statements:  

Some of the statements on this launch are forward-looking statements throughout the which means of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which contain dangers and uncertainties. Forward-looking statements on this press launch embrace, with out limitation, Intelligent Bio Solutions Inc.’s capacity to efficiently develop and commercialize its drug and diagnostic assessments, understand industrial profit from its partnerships and collaborations, and safe regulatory approvals, amongst others. Although Intelligent Bio Solutions Inc. believes that the expectations mirrored in such forward-looking statements are cheap as of the date made, expectations could show to have been materially totally different from the outcomes expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has tried to establish forward-looking statements by terminology, together with “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or different phrases that convey uncertainty of future occasions or outcomes to establish these forward-looking statements. These statements are solely predictions and contain identified and unknown dangers, uncertainties, and different components, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained on this launch communicate solely as of its date. Intelligent Bio Solutions undertakes no obligation to replace any forward-looking statements contained on this launch to replicate occasions or circumstances occurring after its date or to replicate the prevalence of unanticipated occasions.  

Company Contact:  
Intelligent Bio Solutions Inc.  
information@ibs.inc  
LinkedIn¯|¯Twitter  

Investor & Media Contact:¯  
Valter Pinto, Managing Director¯  
KCSA Strategic Communications¯  
PH: (212) 896-1254¯  
INBS@kcsa.com¯  

MoneyMaker FX EA Trading Robot

powered by qhost365.com

Investing.com